Opevesostat Tosilate

5 trials 5 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

5 Recruiting

0 Completed trials

1 Sponsors

21 Countries

Phase III

Phase II/III

Phase I/II

Phase III: 2 Phase II/III: 1 Phase I/II: 2

Oversight events:

35 temporary halts 1 urgent safety measure across 4 trials

View oversight register →

Indications tested

Prostate cancer metastatic 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 5

All trials

5 total

A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Phase III 15 countries Merck Sharp & Dohme LLC
A clinical study of MK-5684 in people with certain solid tumors (MK-5684-015) Recruiting

2024-519563-18-00 Phase II/III 1 country Merck Sharp & Dohme LLC
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting

2024-516036-94-00 Phase I/II 7 countries Merck Sharp & Dohme LLC
Study of MK-5684-based Therapies in Advanced Prostate Cancer Recruiting

2023-506288-33-00 Phase I/II 8 countries Merck Sharp & Dohme LLC
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Phase III 14 countries Merck Sharp & Dohme LLC

Showing 1–5 of 5 trials

← All drugs A–Z